Innocan Pharma Corp. Stock
€0.17
Your prediction
Financial data and news for Innocan Pharma Corp.
sharewise wants to provide you with the best news and tools for Innocan Pharma Corp., so we directly link to the best financial data sources.
Financials
News
![Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million : https://www.irw-press.at/prcom/images/messages/2024/75707/Innocan_052724_ENPRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL1NsYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9120b754244fd10672d252bdbcd508c6d9e40bce/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Innocan_052724_ENPRcom.001.png?locale=us)
Innocan Pharma Reports First Quarter 2024 Results with Revenue Growth of over 4X to $6.8 Million
Herzliya, Israel and Calgary, Alberta - May 27, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
![Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024: https://www.irw-press.at/prcom/images/messages/2024/73634/InnocanPharma_EN_PRcom.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHMzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f6d0dc131f57348b693fa831da2fcc367dd82541/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/InnocanPharma_EN_PRcom.001.jpeg?locale=us)
Innocan Pharma to participate in the White Label World Expo on February 27-28th, 2024
Herzliya, Israel and Calgary, Alberta - (February 20, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to announce that CEO Iris
![Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center
Herzliya, Israel and Calgary, Alberta – July 26, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
![Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Innocan Pharma Engages Pain Management Expert in Preparation for Upcoming FDA Meeting
Herzliya, Israel and Calgary, Alberta - July 2, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
![Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs
Herzliya, Israel and Calgary, Alberta - June 11, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
![FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain
The regulatory approval process with the U.S. Food and Drug Administration has commenced for Innocan’s LPT-CBD release technology, marking a key step in the advancement of non-opioid pain
![Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
Herzliya, Israel and Calgary, Alberta - May 09, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and
![Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
With its submission of a Pre-IND Meeting Request Letter, Innocan initiates the regulatory process with the U.S. Food and Drug Administration (FDA) for the approval of its prolonged CBD
![Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Herzliya, Israel and Calgary, Alberta – April 1, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company
![Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Innocan Pharma paves its way to LPT-CBD Chemistry, Manufacturing and Controls (CMC), key milestones for FDA approval.
Herzliya, Israel and Calgary, Alberta - March 25, 2024 - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug
![Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of Approximately C$2 Million
NOT FOR DISSEMINATION IN OR INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
HERZLIYA, Israel and CALGARY, Alberta – March 15, 2024 – Innocan Pharma Corporation (the “
![Innocan Pharma’s LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Innocan Pharma’s LPT-CBD Has the Potential to Support a new Therapeutic Venue for Neurological Disorders According to Recent Study
Innocan Announces Notice of Intention to Complete a Private Placement of Units
Herzliya, Israel and Calgary, Alberta – March 5, 2024 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4)
![Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits
Herzliya, Israel and Calgary, Alberta – February 26, 2023 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and
![Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Innocan Provides Corporate Update & Preliminary Q4 and Fiscal Year 2023 Financial Highlights
Herzliya, Israel and Calgary, Alberta - (February 13, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), is pleased to provide the
![Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Innocan Pharma to provide a corporate update via Zoom livestream on February 12, 2024, at 4:00pm EST
Herzliya, Israel and Calgary, Alberta - (February 5, 2024) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan”), is pleased to announce that it will provide a